Lin Zhen, Song Yanfang, Qiu Yaling, Shi Pengchong, Zeng Menglu, Cao Yingping, Zhu Xianjin
Department of Clinical Laboratory, Fujian Medical University Union Hospital, 29 Xinquan Road, Fuzhou, Fujian 350001, China.
Department of Clinical Laboratory, Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, 602 Bayiqi Road, Fuzhou, Fujian 350001, China.
Biomark Med. 2022 Oct;16(15):1121-1128. doi: 10.2217/bmm-2022-0290. Epub 2023 Jan 6.
To investigate the role of serum CYR61 as a biomarker for the diagnosis of breast cancer and to analyze the association between serum CYR61 levels and the clinicopathological features in breast cancer patients. Serum CYR61 was measured in breast cancer patients and healthy controls by ELISA. The serum levels of CYR61 in breast cancer patients were higher than those in healthy controls. The area under the receiver operating characteristic curve for CYR61 was higher than that for carcinoembryonic antigen and carbohydrate antigen 15-3. The increased CYR61 levels were correlated with menopausal status and Ki67 expression. Serum CYR61 might be a novel biomarker to assist the diagnosis and clinicopathological status assessment of breast cancer.
探讨血清CYR61作为乳腺癌诊断生物标志物的作用，并分析血清CYR61水平与乳腺癌患者临床病理特征之间的关联。采用酶联免疫吸附测定法（ELISA）检测乳腺癌患者和健康对照者血清中的CYR61。乳腺癌患者血清CYR61水平高于健康对照者。CYR61的受试者工作特征曲线下面积高于癌胚抗原和糖类抗原15-3。CYR61水平升高与绝经状态和Ki67表达相关。血清CYR61可能是协助乳腺癌诊断及临床病理状态评估的新型生物标志物。
